Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Carisoprodol (compound)

Summary
General Info

PubChem

PubChem Compound 2576

PubChem Compound 2576

Name:	Carisoprodol
PubChem Compound ID:	2576
Description:	A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Molecular formula:	C₁₂H₂₄N₂O₄
Molecular weight:	260.33 g/mol
Synonyms:	Carisol; MLS000028401; Coprobate; 78-44-4; Flexidon; Caprodat; Carsodol; Flexartel; Muslax; Carisoma. show more » Carisol; MLS000028401; Coprobate; 78-44-4; Flexidon; Caprodat; Carsodol; Flexartel; Muslax; Carisoma; Carisoprodate; Cap-O-Tran; BRN 1791537; Somadril; SPBio_002345; Isobamate; NSC 172124; Rela; Scutamil-C; Carisoprodolo [DCIT]; Mediquil; Soma; Calenfa; Somanil; 4-04-00-00520 (Beilstein Handbook Reference); Artifar; KBio1_000816; Carsodal; Meprocon; Tonolyt isopropyl meprobamate; Listaflex; Brianil; Mioratrina; Carisoprodatum; Isoprothane; Mioriodol; Sch 7307; KBioGR_000730; Carbamic acid, isopropyl-, 2-(hydroxymethyl)-2-methylpentyl ester carbamate (ester); Prestwick0_000423; Mioartrina; NSC172124; N-Isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate; Carisoprodol (JAN/USP); Miolisodal; Mioril; Fibrosona; C07927; Spectrum3_000328; Meprobamate; Prestwick_50; Apesan; Isoprotan; Carbamic acid, ester with 2-(hydroxymethyl)-2-methylpentylisopropyl carbamate; KBio2_005678; Arusal; N-Isopropyl-2-methyl-2-propyl-1,3-propanediol, dicarbamate; KBio2_000542; NCI-C56235; Carisoprodol; EINECS 201-118-7; EU-0100319; Flexagilt; Flexartal; Isopropyl meprobamate; 8053-63-2; Carbamic acid, (1-methylethyl)-, 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester; 1, 3-Propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate; Flexal; Skutamil; Isopropylcarbamic acid, ester with 2-(hydroxymethyl)-2-methylpentyl carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester); Nospasm; Carbamic acid, isopropyl-, 2- (hydroxymethyl)-2-methylpentyl ester carbamate (ester); Somalgit; (1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester; Meprodat; Carbamic acid, ester with 2-(hydroxymethyl)-2-methylpentyl isopropylcarbamate; Carisoprodolum [INN-Latin]; Sanoma; HSDB 3021; NINDS_000816; D00768; Relasom; Caridolin; Stialgin; KBio3_001155; Carbamic acid, ester with 2-methyl-2-propyl-1,3-propanediol isopropylcarbamate; Carlsodol; KBio2_003110; SPBio_001105; Flexagit; Relax; Spectrum4_000265; Spectrum_000102; 2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate; Izoprotan; Spectrum2_001153; Miolisodol; SMR000058433; Chinchen; Neotica; DivK1c_000816; Prestwick1_000423; Atonalyt; Isomeprobamate; Soma (TN); CCRIS 4764; Carlsoprol; Isoprotane; NCGC00089734-02; Carisoprodol [USAN:BAN:INN]; Carlsoma; Domarax; Diolene; Carbamic acid, (1-methylethyl)-, 2-[[(aminocarbonyl)oxy]methyl]-2-methylpentyl ester; CB 8019; KBioSS_000542 show less «

DrugBank

Identification

Name:	Carisoprodol
Name (isomeric):	DB00395
Drug Type:	small molecule
Description:	A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Synonyms:	Isoprothane; Carisoprodatum; Carisoprodate; Isoprotane; Isomeprobamate
Brand:	Arusal, Soma, Miolisodal, Scutamil-C, Mioartrina, Carisoma, Flexal, Chinchen, Skutamil, Apesan, Mioratrina, Flexagilt, Atonalyt, Neotica, Mioril, Artifar, Somanil, Meprodat, Fibrosona, Flexidon, Muslax, Flexagit, Listaflex, Flexartal, Nospasm, Sanoma, Caridolin, Relasom
Category:	Muscle Relaxants, Central, Muscle Relaxants, Skeletal Muscle Relaxants
CAS number:	78-44-4

Pharmacology

Indication:	For the relief of discomfort associated with acute, painful, musculoskeletal conditions.
Pharmacology:	Carisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.
Mechanism of Action:	Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet kno... show more » Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known. show less «
Protein binding:	60%
Biotransformation:	Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.
Route of elimination:	Carisoprodol is eliminated by both renal and non-renal routes.
Half Life:	8 hours
Clearance:	oral cl=0.772 L/hour/kg [Women] oral cl=0.38 L/hour/kg [Men]
Toxicity:	Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Take without regard to meals.

Drug interaction:

Isoniazid	Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Fluconazole	Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Droperidol	Droperidol may enhance the CNS depressant effect of carisoprodol. Consider dose reductions of droperidol or of other CNS agents with concomitant use.
Methotrimeprazine	Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy.
Modafinil	Strong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.

Isoniazid	Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Fluconazole	Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Droperidol	Droperidol may enhance the CNS depressant effect of carisoprodol. Consider dose reductions of droperidol or of other CNS agents with concomitant use.
Methotrimeprazine	Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy.
Modafinil	Strong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Delavirdine	Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Triprolidine	The CNS depressants, Triprolidine and Carisoprodol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Ticlopidine	Ticlopidine may decrease the metabolism and clearance of Carisoprodol. Consider alternate therapy or monitor for adverse/toxic effects of Carisoprodol if Ticlopidine is initiated, discontinued or dose changed.
Gemfibrozil	Strong CYP2C19 inhibitors such as gemfibrozil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Sitaxentan	Strong CYP2C19 inhibitors such as sitaxentan may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
Fluvoxamine	Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.

Enzymes

Cytochrome P450 2C19